Frédéric Fiteni1, Dewi Vernerey2, Franck Bonnetain3, Fabien Vaylet4, Hélène Sennélart5, Jean Trédaniel6, Denis Moro-Sibilot7, Dominique Herman8, Hélène Laizé9, Philippe Masson10, Marc Derollez11, Christelle Clément-Duchêne12, Bernard Milleron13, Franck Morin13, Gérard Zalcman14, Elisabeth Quoix15, Virginie Westeel16. 1. University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit, Besançon, France; University Hospital of Besançon, Department of Medical Oncology, Besançon, France; EA 3181 University of Franche-Comté, Besançon, France. Electronic address: fredericfiteni@gmail.com. 2. University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit, Besançon, France. 3. University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit, Besançon, France; EA 3181 University of Franche-Comté, Besançon, France; Platform Quality of Life and Cancer, France. 4. Instruction Hospital of the Armies, Department of Pneumology, Percy-Clamart, France. 5. CLCC René Gauducheau, Department of Medical Oncology, Nantes, France. 6. St Joseph Hospital, Department of Medical Oncology, Paris, France. 7. University Hospital of Grenoble, Pneumology Department, Grenoble, France. 8. Hospital of Nevers, Pneumology Department, Nevers, France. 9. Hospital of Sceaux, Pneumology Department, Sceaux, France. 10. Hospital of Cholet, Pneumology Department, Cholet, France. 11. Private Hospital, Pneumology Department, Maubeuge, France. 12. University Hospital of Nancy, Pneumology Department, Nancy, France. 13. Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France. 14. Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France; University Hospital of Caen, Pneumology Department, Caen, France. 15. Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France; University Hospital of Strasbourg, Pneumology Department, France. 16. Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France; University Hospital of Besançon, Pneumology Department, France.
Abstract
BACKGROUND: We investigated whether the health-related quality of life (HRQoL) score is a prognostic factor for overall survival (OS) in elderly patients with advanced non-small-cell lung cancer (NSCLC). METHODS: We included 451 NSCLC patients aged 70-89 years enrolled in the Intergroupe Francophone de Cancérologie Thoracique 0501 trial, using scores of the European Organisation for Research and Treatment ofCancer Quality of Life Questionnaire Core 30 at baseline to investigate the prognostic value of HRQoL for OS, in addition to conventional factors. Cox regression model was used for both univariate and multivariate analyses of OS. RESULTS:Global health status (GH) dimension score at baseline was associated with favourable OS when adjusted for clinical, functional, and histological factors (hazard ratio [HR]: 0.986; 95% confidence interval [CI]: 0.980-0.992). We distinguished three groups according to GH score: high (GH <46), intermediate (46 ≤ GH ≤ 67), and low (GH >67) mortality risk. The median OS values were 14.5, 8.2, and 5.3 months in the low-, intermediate-, and high-risk categories, respectively (log-rank P <0.0001). In the high-risk group, doublet chemotherapy was not associated with favourable OS (HR: 0.70; 95% CI: 0.49-1.003; P=0.052), whereas in the intermediate- and low-risk groups, doublet chemotherapy was associated with favourable OS (HR: 0.72; 95% CI: 0.54-0.96; P=0.023 and HR: 0.50; 95% CI: 0.30-0.84; P=0.0089, respectively). CONCLUSION: This study supports the additional prognostic value of HRQoL data at diagnosis to identify vulnerable subpopulations in elderly NSCLC patients. HRQoL could thus be valuable in selecting patients who will benefit from doublet chemotherapy.
RCT Entities:
BACKGROUND: We investigated whether the health-related quality of life (HRQoL) score is a prognostic factor for overall survival (OS) in elderly patients with advanced non-small-cell lung cancer (NSCLC). METHODS: We included 451 NSCLCpatients aged 70-89 years enrolled in the Intergroupe Francophone de Cancérologie Thoracique 0501 trial, using scores of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 at baseline to investigate the prognostic value of HRQoL for OS, in addition to conventional factors. Cox regression model was used for both univariate and multivariate analyses of OS. RESULTS: Global health status (GH) dimension score at baseline was associated with favourable OS when adjusted for clinical, functional, and histological factors (hazard ratio [HR]: 0.986; 95% confidence interval [CI]: 0.980-0.992). We distinguished three groups according to GH score: high (GH <46), intermediate (46 ≤ GH ≤ 67), and low (GH >67) mortality risk. The median OS values were 14.5, 8.2, and 5.3 months in the low-, intermediate-, and high-risk categories, respectively (log-rank P <0.0001). In the high-risk group, doublet chemotherapy was not associated with favourable OS (HR: 0.70; 95% CI: 0.49-1.003; P=0.052), whereas in the intermediate- and low-risk groups, doublet chemotherapy was associated with favourable OS (HR: 0.72; 95% CI: 0.54-0.96; P=0.023 and HR: 0.50; 95% CI: 0.30-0.84; P=0.0089, respectively). CONCLUSION: This study supports the additional prognostic value of HRQoL data at diagnosis to identify vulnerable subpopulations in elderly NSCLCpatients. HRQoL could thus be valuable in selecting patients who will benefit from doublet chemotherapy.
Authors: Kuan Liao; Tianxiao Wang; Jake Coomber-Moore; David C Wong; Fabio Gomes; Corinne Faivre-Finn; Matthew Sperrin; Janelle Yorke; Sabine N van der Veer Journal: BMC Cancer Date: 2022-10-19 Impact factor: 4.638
Authors: Jin-Ah Sim; Young Ae Kim; Ju Han Kim; Jong Mog Lee; Moon Soo Kim; Young Mog Shim; Jae Ill Zo; Young Ho Yun Journal: Sci Rep Date: 2020-07-01 Impact factor: 4.379